Department of Medical Oncology, Mediterranean Institut of Oncology, Via Penninazzo, 7, 95029 Viagrande, Italy.
J Oncol. 2012;2012:391629. doi: 10.1155/2012/391629. Epub 2012 Oct 22.
Thyroid cancer is the most common endocrine tumor. Thyroidectomy, radioactive iodine, and TSH suppression represent the standard treatment for differentiated thyroid cancer. Since chemotherapy has been shown to be unsuccessful in case of advanced thyroid carcinomas, the research for new therapies is fundamental. In this paper, we reviewed the recent literature reports (pubmed, medline, EMBASE database, and abstracts published in meeting proceedings) on new treatments in advanced nonmedullary and medullary thyroid carcinomas. Studies of many tyrosine kinase inhibitors as well as antiangiogenic inhibitors suggest that patients with thyroid cancer could have an advantage with new target therapy. We summarized both the results obtained and the toxic effects associated with these treatments reported in clinical trials. Reported data in this paper are encouraging, but further trials are necessary to obtain a more effective result in thyroid carcinoma treatment.
甲状腺癌是最常见的内分泌肿瘤。甲状腺切除术、放射性碘和 TSH 抑制是分化型甲状腺癌的标准治疗方法。由于化疗在晚期甲状腺癌中已被证明无效，因此研究新的治疗方法至关重要。本文综述了最近关于晚期非髓样和髓样甲状腺癌新治疗方法的文献报告（pubmed、medline、EMBASE 数据库和会议论文集摘要）。许多酪氨酸激酶抑制剂和抗血管生成抑制剂的研究表明，甲状腺癌患者可能受益于新的靶向治疗。我们总结了临床试验中报告的这些治疗方法的结果和相关毒性作用。本文报告的数据令人鼓舞，但需要进一步的试验才能在甲状腺癌治疗中获得更有效的结果。
